nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Pulmonary hypertension—Phentermine—obesity	0.0164	0.0506	CcSEcCtD
Carfilzomib—Pulmonary hypertension—Diethylpropion—obesity	0.0143	0.044	CcSEcCtD
Carfilzomib—PSMB10—respiratory system—obesity	0.0134	0.0594	CbGeAlD
Carfilzomib—Chest wall pain—Bupropion—obesity	0.0129	0.0398	CcSEcCtD
Carfilzomib—PSMB8—islet of Langerhans—obesity	0.00917	0.0405	CbGeAlD
Carfilzomib—PSMB10—adipose tissue—obesity	0.00908	0.0401	CbGeAlD
Carfilzomib—PSMB10—digestive system—obesity	0.00855	0.0377	CbGeAlD
Carfilzomib—Herpes virus infection—Bupropion—obesity	0.00848	0.0262	CcSEcCtD
Carfilzomib—PSMB10—adrenal gland—obesity	0.00814	0.036	CbGeAlD
Carfilzomib—PSMB5—islet of Langerhans—obesity	0.0081	0.0358	CbGeAlD
Carfilzomib—PSMB8—adrenal cortex—obesity	0.00727	0.0321	CbGeAlD
Carfilzomib—PSMB1—islet of Langerhans—obesity	0.00708	0.0313	CbGeAlD
Carfilzomib—PSMB10—endocrine gland—obesity	0.00706	0.0312	CbGeAlD
Carfilzomib—PSMB10—Tamoxifen—Benzphetamine—obesity	0.00704	1	CbGdCrCtD
Carfilzomib—PSMB2—islet of Langerhans—obesity	0.00691	0.0305	CbGeAlD
Carfilzomib—PSMB1—respiratory system—obesity	0.00669	0.0295	CbGeAlD
Carfilzomib—PSMB2—respiratory system—obesity	0.00653	0.0288	CbGeAlD
Carfilzomib—PSMB5—adrenal cortex—obesity	0.00642	0.0284	CbGeAlD
Carfilzomib—PSMB10—liver—obesity	0.00637	0.0281	CbGeAlD
Carfilzomib—Musculoskeletal chest pain—Bupropion—obesity	0.00607	0.0187	CcSEcCtD
Carfilzomib—PSMB8—pituitary gland—obesity	0.00587	0.0259	CbGeAlD
Carfilzomib—PSMB8—adipose tissue—obesity	0.00585	0.0258	CbGeAlD
Carfilzomib—PSMB1—adrenal cortex—obesity	0.00561	0.0248	CbGeAlD
Carfilzomib—PSMB2—adrenal cortex—obesity	0.00548	0.0242	CbGeAlD
Carfilzomib—PSMB8—adrenal gland—obesity	0.00525	0.0232	CbGeAlD
Carfilzomib—PSMB5—pituitary gland—obesity	0.00519	0.0229	CbGeAlD
Carfilzomib—PSMB5—adipose tissue—obesity	0.00517	0.0228	CbGeAlD
Carfilzomib—PSMB1—cardiovascular system—obesity	0.00512	0.0226	CbGeAlD
Carfilzomib—PSMB2—cardiovascular system—obesity	0.005	0.0221	CbGeAlD
Carfilzomib—PSMB5—adrenal gland—obesity	0.00464	0.0205	CbGeAlD
Carfilzomib—PSMB1—pituitary gland—obesity	0.00454	0.02	CbGeAlD
Carfilzomib—PSMB1—adipose tissue—obesity	0.00452	0.0199	CbGeAlD
Carfilzomib—PSMB2—pituitary gland—obesity	0.00443	0.0195	CbGeAlD
Carfilzomib—Pentagastrin—BCHE—obesity	0.00441	0.724	CrCbGaD
Carfilzomib—PSMB2—adipose tissue—obesity	0.00441	0.0195	CbGeAlD
Carfilzomib—PSMB1—digestive system—obesity	0.00425	0.0188	CbGeAlD
Carfilzomib—Cardiac arrest—Phentermine—obesity	0.00421	0.013	CcSEcCtD
Carfilzomib—PSMB2—digestive system—obesity	0.00415	0.0183	CbGeAlD
Carfilzomib—PSMB8—liver—obesity	0.0041	0.0181	CbGeAlD
Carfilzomib—Hepatic failure—Cimetidine—obesity	0.00408	0.0126	CcSEcCtD
Carfilzomib—PSMB1—adrenal gland—obesity	0.00405	0.0179	CbGeAlD
Carfilzomib—PSMB2—adrenal gland—obesity	0.00395	0.0175	CbGeAlD
Carfilzomib—Musculoskeletal chest pain—Topiramate—obesity	0.00387	0.0119	CcSEcCtD
Carfilzomib—PSMB5—liver—obesity	0.00362	0.016	CbGeAlD
Carfilzomib—Neuritis—Sibutramine—obesity	0.00362	0.0112	CcSEcCtD
Carfilzomib—PSMB1—endocrine gland—obesity	0.00351	0.0155	CbGeAlD
Carfilzomib—Blood creatinine increased—Cimetidine—obesity	0.00344	0.0106	CcSEcCtD
Carfilzomib—PSMB2—endocrine gland—obesity	0.00343	0.0151	CbGeAlD
Carfilzomib—Acute coronary syndrome—Phentermine—obesity	0.00337	0.0104	CcSEcCtD
Carfilzomib—PSMB1—liver—obesity	0.00317	0.014	CbGeAlD
Carfilzomib—PSMB2—liver—obesity	0.00309	0.0136	CbGeAlD
Carfilzomib—Neutropenia—Cimetidine—obesity	0.00296	0.00915	CcSEcCtD
Carfilzomib—Lymphopenia—Topiramate—obesity	0.00293	0.00904	CcSEcCtD
Carfilzomib—Pneumonia—Cimetidine—obesity	0.00284	0.00877	CcSEcCtD
Carfilzomib—Anorexia—Benzphetamine—obesity	0.00279	0.0086	CcSEcCtD
Carfilzomib—Renal failure—Cimetidine—obesity	0.00278	0.00858	CcSEcCtD
Carfilzomib—Insomnia—Methamphetamine—obesity	0.00274	0.00846	CcSEcCtD
Carfilzomib—Insomnia—Benzphetamine—obesity	0.00264	0.00816	CcSEcCtD
Carfilzomib—Constipation—Methamphetamine—obesity	0.00259	0.008	CcSEcCtD
Carfilzomib—Hypophosphataemia—Topiramate—obesity	0.00258	0.00796	CcSEcCtD
Carfilzomib—Decreased appetite—Benzphetamine—obesity	0.00254	0.00784	CcSEcCtD
Carfilzomib—Anorexia—Phendimetrazine—obesity	0.00254	0.00784	CcSEcCtD
Carfilzomib—Insomnia—Phendimetrazine—obesity	0.00241	0.00744	CcSEcCtD
Carfilzomib—Sepsis—Sibutramine—obesity	0.00234	0.00723	CcSEcCtD
Carfilzomib—Decreased appetite—Phendimetrazine—obesity	0.00232	0.00715	CcSEcCtD
Carfilzomib—Hypertension—Phentermine—obesity	0.0023	0.00711	CcSEcCtD
Carfilzomib—Constipation—Phendimetrazine—obesity	0.00228	0.00703	CcSEcCtD
Carfilzomib—Hepatic failure—Orlistat—obesity	0.00225	0.00695	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Sibutramine—obesity	0.00216	0.00667	CcSEcCtD
Carfilzomib—Leukopenia—Diethylpropion—obesity	0.00208	0.00641	CcSEcCtD
Carfilzomib—Diarrhoea—Methamphetamine—obesity	0.00207	0.0064	CcSEcCtD
Carfilzomib—Insomnia—Phenylpropanolamine—obesity	0.00206	0.00635	CcSEcCtD
Carfilzomib—Dyspnoea—Phenylpropanolamine—obesity	0.00203	0.00626	CcSEcCtD
Carfilzomib—Dizziness—Methamphetamine—obesity	0.002	0.00619	CcSEcCtD
Carfilzomib—Diarrhoea—Benzphetamine—obesity	0.002	0.00617	CcSEcCtD
Carfilzomib—Leukopenia—Cimetidine—obesity	0.00198	0.0061	CcSEcCtD
Carfilzomib—Insomnia—Phentermine—obesity	0.00197	0.00608	CcSEcCtD
Carfilzomib—Pain in extremity—Sibutramine—obesity	0.00196	0.00605	CcSEcCtD
Carfilzomib—Constipation—Phenylpropanolamine—obesity	0.00195	0.00601	CcSEcCtD
Carfilzomib—Dizziness—Benzphetamine—obesity	0.00193	0.00597	CcSEcCtD
Carfilzomib—Headache—Methamphetamine—obesity	0.0019	0.00586	CcSEcCtD
Carfilzomib—Arthralgia—Cimetidine—obesity	0.00188	0.0058	CcSEcCtD
Carfilzomib—Fatigue—Phentermine—obesity	0.00188	0.0058	CcSEcCtD
Carfilzomib—Cardiac arrest—Sibutramine—obesity	0.00186	0.00575	CcSEcCtD
Carfilzomib—Constipation—Phentermine—obesity	0.00186	0.00575	CcSEcCtD
Carfilzomib—Hypokalaemia—Orlistat—obesity	0.00184	0.00569	CcSEcCtD
Carfilzomib—Blood creatinine increased—Sibutramine—obesity	0.00184	0.00567	CcSEcCtD
Carfilzomib—Headache—Benzphetamine—obesity	0.00183	0.00565	CcSEcCtD
Carfilzomib—Diarrhoea—Phendimetrazine—obesity	0.00182	0.00563	CcSEcCtD
Carfilzomib—Hypokalaemia—Sibutramine—obesity	0.00178	0.0055	CcSEcCtD
Carfilzomib—Thrombocytopenia—Cimetidine—obesity	0.00176	0.00545	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Sibutramine—obesity	0.00176	0.00545	CcSEcCtD
Carfilzomib—Dizziness—Phendimetrazine—obesity	0.00176	0.00544	CcSEcCtD
Carfilzomib—Nausea—Benzphetamine—obesity	0.00174	0.00536	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Diethylpropion—obesity	0.00173	0.00533	CcSEcCtD
Carfilzomib—Insomnia—Diethylpropion—obesity	0.00171	0.00529	CcSEcCtD
Carfilzomib—Pain in extremity—Bupropion—obesity	0.00171	0.00527	CcSEcCtD
Carfilzomib—Dyspnoea—Diethylpropion—obesity	0.00169	0.00521	CcSEcCtD
Carfilzomib—Ritonavir—CYP2E1—obesity	0.00168	0.276	CrCbGaD
Carfilzomib—Headache—Phendimetrazine—obesity	0.00167	0.00515	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Cimetidine—obesity	0.00164	0.00507	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Orlistat—obesity	0.00163	0.00502	CcSEcCtD
Carfilzomib—Constipation—Diethylpropion—obesity	0.00162	0.005	CcSEcCtD
Carfilzomib—Nausea—Phendimetrazine—obesity	0.00158	0.00488	CcSEcCtD
Carfilzomib—Asthenia—Phentermine—obesity	0.00156	0.00482	CcSEcCtD
Carfilzomib—Fatigue—Cimetidine—obesity	0.00155	0.0048	CcSEcCtD
Carfilzomib—Constipation—Cimetidine—obesity	0.00154	0.00476	CcSEcCtD
Carfilzomib—Renal failure—Orlistat—obesity	0.00153	0.00473	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Orlistat—obesity	0.00153	0.00472	CcSEcCtD
Carfilzomib—Hyperglycaemia—Sibutramine—obesity	0.00153	0.00472	CcSEcCtD
Carfilzomib—Pneumonia—Sibutramine—obesity	0.00152	0.00469	CcSEcCtD
Carfilzomib—Dizziness—Phenylpropanolamine—obesity	0.0015	0.00464	CcSEcCtD
Carfilzomib—Diarrhoea—Phentermine—obesity	0.00149	0.0046	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Sibutramine—obesity	0.00149	0.0046	CcSEcCtD
Carfilzomib—Renal failure—Sibutramine—obesity	0.00148	0.00458	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Sibutramine—obesity	0.00148	0.00457	CcSEcCtD
Carfilzomib—Vomiting—Phenylpropanolamine—obesity	0.00145	0.00447	CcSEcCtD
Carfilzomib—Dizziness—Phentermine—obesity	0.00144	0.00445	CcSEcCtD
Carfilzomib—Body temperature increased—Cimetidine—obesity	0.00142	0.0044	CcSEcCtD
Carfilzomib—Vomiting—Phentermine—obesity	0.00138	0.00427	CcSEcCtD
Carfilzomib—Oedema peripheral—Orlistat—obesity	0.00138	0.00426	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Bupropion—obesity	0.00137	0.00424	CcSEcCtD
Carfilzomib—Headache—Phentermine—obesity	0.00136	0.00421	CcSEcCtD
Carfilzomib—Nausea—Phenylpropanolamine—obesity	0.00135	0.00417	CcSEcCtD
Carfilzomib—Hypoaesthesia—Sibutramine—obesity	0.00135	0.00416	CcSEcCtD
Carfilzomib—Oedema peripheral—Sibutramine—obesity	0.00134	0.00412	CcSEcCtD
Carfilzomib—Hyperglycaemia—Bupropion—obesity	0.00133	0.00411	CcSEcCtD
Carfilzomib—Pneumonia—Bupropion—obesity	0.00132	0.00409	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Bupropion—obesity	0.0013	0.00401	CcSEcCtD
Carfilzomib—Diarrhoea—Diethylpropion—obesity	0.0013	0.004	CcSEcCtD
Carfilzomib—Nausea—Phentermine—obesity	0.00129	0.00399	CcSEcCtD
Carfilzomib—Asthenia—Cimetidine—obesity	0.00129	0.00399	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Bupropion—obesity	0.00129	0.00398	CcSEcCtD
Carfilzomib—Dizziness—Diethylpropion—obesity	0.00125	0.00387	CcSEcCtD
Carfilzomib—Diarrhoea—Cimetidine—obesity	0.00123	0.00381	CcSEcCtD
Carfilzomib—Chills—Sibutramine—obesity	0.00122	0.00375	CcSEcCtD
Carfilzomib—Hepatic failure—Topiramate—obesity	0.00121	0.00374	CcSEcCtD
Carfilzomib—Vomiting—Diethylpropion—obesity	0.0012	0.00372	CcSEcCtD
Carfilzomib—Dizziness—Cimetidine—obesity	0.00119	0.00368	CcSEcCtD
Carfilzomib—Headache—Diethylpropion—obesity	0.00119	0.00366	CcSEcCtD
Carfilzomib—Back pain—Orlistat—obesity	0.00118	0.00364	CcSEcCtD
Carfilzomib—Hypoaesthesia—Bupropion—obesity	0.00118	0.00363	CcSEcCtD
Carfilzomib—Muscle spasms—Orlistat—obesity	0.00117	0.00362	CcSEcCtD
Carfilzomib—Oedema peripheral—Bupropion—obesity	0.00116	0.00359	CcSEcCtD
Carfilzomib—Vomiting—Cimetidine—obesity	0.00115	0.00354	CcSEcCtD
Carfilzomib—Back pain—Sibutramine—obesity	0.00114	0.00352	CcSEcCtD
Carfilzomib—Muscle spasms—Sibutramine—obesity	0.00113	0.0035	CcSEcCtD
Carfilzomib—Headache—Cimetidine—obesity	0.00113	0.00349	CcSEcCtD
Carfilzomib—Nausea—Diethylpropion—obesity	0.00113	0.00347	CcSEcCtD
Carfilzomib—Cardiac disorder—Bupropion—obesity	0.0011	0.00339	CcSEcCtD
Carfilzomib—Hyponatraemia—Topiramate—obesity	0.00109	0.00337	CcSEcCtD
Carfilzomib—Anaemia—Sibutramine—obesity	0.00109	0.00337	CcSEcCtD
Carfilzomib—Pain in extremity—Topiramate—obesity	0.00109	0.00336	CcSEcCtD
Carfilzomib—Nausea—Cimetidine—obesity	0.00107	0.0033	CcSEcCtD
Carfilzomib—Cough—Orlistat—obesity	0.00106	0.00328	CcSEcCtD
Carfilzomib—Chills—Bupropion—obesity	0.00106	0.00327	CcSEcCtD
Carfilzomib—Leukopenia—Sibutramine—obesity	0.00106	0.00326	CcSEcCtD
Carfilzomib—ABCB1—islet of Langerhans—obesity	0.00106	0.00466	CbGeAlD
Carfilzomib—Cough—Sibutramine—obesity	0.00103	0.00318	CcSEcCtD
Carfilzomib—Blood creatinine increased—Topiramate—obesity	0.00102	0.00315	CcSEcCtD
Carfilzomib—Hypertension—Sibutramine—obesity	0.00102	0.00314	CcSEcCtD
Carfilzomib—Arthralgia—Sibutramine—obesity	0.001	0.0031	CcSEcCtD
Carfilzomib—ABCB1—respiratory system—obesity	0.000997	0.0044	CbGeAlD
Carfilzomib—Back pain—Bupropion—obesity	0.000995	0.00307	CcSEcCtD
Carfilzomib—Hypokalaemia—Topiramate—obesity	0.00099	0.00306	CcSEcCtD
Carfilzomib—Muscle spasms—Bupropion—obesity	0.000989	0.00305	CcSEcCtD
Carfilzomib—Infection—Orlistat—obesity	0.000989	0.00305	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Topiramate—obesity	0.00098	0.00303	CcSEcCtD
Carfilzomib—Infection—Sibutramine—obesity	0.000957	0.00295	CcSEcCtD
Carfilzomib—Anaemia—Bupropion—obesity	0.000951	0.00294	CcSEcCtD
Carfilzomib—Thrombocytopenia—Sibutramine—obesity	0.000943	0.00291	CcSEcCtD
Carfilzomib—Leukopenia—Bupropion—obesity	0.000921	0.00284	CcSEcCtD
Carfilzomib—Anorexia—Sibutramine—obesity	0.000918	0.00283	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Orlistat—obesity	0.000907	0.0028	CcSEcCtD
Carfilzomib—Insomnia—Orlistat—obesity	0.0009	0.00278	CcSEcCtD
Carfilzomib—Cough—Bupropion—obesity	0.000898	0.00277	CcSEcCtD
Carfilzomib—Hypertension—Bupropion—obesity	0.000888	0.00274	CcSEcCtD
Carfilzomib—Neutropenia—Topiramate—obesity	0.00088	0.00272	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Sibutramine—obesity	0.000877	0.00271	CcSEcCtD
Carfilzomib—Arthralgia—Bupropion—obesity	0.000876	0.0027	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Topiramate—obesity	0.000874	0.0027	CcSEcCtD
Carfilzomib—Insomnia—Sibutramine—obesity	0.000871	0.00269	CcSEcCtD
Carfilzomib—Decreased appetite—Orlistat—obesity	0.000865	0.00267	CcSEcCtD
Carfilzomib—Dyspnoea—Sibutramine—obesity	0.000859	0.00265	CcSEcCtD
Carfilzomib—Fatigue—Orlistat—obesity	0.000858	0.00265	CcSEcCtD
Carfilzomib—Pain—Orlistat—obesity	0.000851	0.00263	CcSEcCtD
Carfilzomib—Hyperglycaemia—Topiramate—obesity	0.000849	0.00262	CcSEcCtD
Carfilzomib—Pneumonia—Topiramate—obesity	0.000844	0.0026	CcSEcCtD
Carfilzomib—Decreased appetite—Sibutramine—obesity	0.000837	0.00258	CcSEcCtD
Carfilzomib—ABCB1—adrenal cortex—obesity	0.000837	0.00369	CbGeAlD
Carfilzomib—Infection—Bupropion—obesity	0.000834	0.00257	CcSEcCtD
Carfilzomib—Renal failure—Topiramate—obesity	0.000824	0.00254	CcSEcCtD
Carfilzomib—Pain—Sibutramine—obesity	0.000824	0.00254	CcSEcCtD
Carfilzomib—Constipation—Sibutramine—obesity	0.000824	0.00254	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Topiramate—obesity	0.000822	0.00254	CcSEcCtD
Carfilzomib—Thrombocytopenia—Bupropion—obesity	0.000822	0.00254	CcSEcCtD
Carfilzomib—Anorexia—Bupropion—obesity	0.0008	0.00247	CcSEcCtD
Carfilzomib—Body temperature increased—Orlistat—obesity	0.000787	0.00243	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Bupropion—obesity	0.000765	0.00236	CcSEcCtD
Carfilzomib—ABCB1—cardiovascular system—obesity	0.000764	0.00337	CbGeAlD
Carfilzomib—Body temperature increased—Sibutramine—obesity	0.000761	0.00235	CcSEcCtD
Carfilzomib—Insomnia—Bupropion—obesity	0.000759	0.00234	CcSEcCtD
Carfilzomib—Hypoaesthesia—Topiramate—obesity	0.000749	0.00231	CcSEcCtD
Carfilzomib—Dyspnoea—Bupropion—obesity	0.000749	0.00231	CcSEcCtD
Carfilzomib—Oedema peripheral—Topiramate—obesity	0.000742	0.00229	CcSEcCtD
Carfilzomib—Decreased appetite—Bupropion—obesity	0.00073	0.00225	CcSEcCtD
Carfilzomib—Fatigue—Bupropion—obesity	0.000724	0.00223	CcSEcCtD
Carfilzomib—Constipation—Bupropion—obesity	0.000718	0.00222	CcSEcCtD
Carfilzomib—Pain—Bupropion—obesity	0.000718	0.00222	CcSEcCtD
Carfilzomib—Asthenia—Orlistat—obesity	0.000714	0.0022	CcSEcCtD
Carfilzomib—Cardiac disorder—Topiramate—obesity	0.000699	0.00216	CcSEcCtD
Carfilzomib—Asthenia—Sibutramine—obesity	0.000691	0.00213	CcSEcCtD
Carfilzomib—Diarrhoea—Orlistat—obesity	0.000681	0.0021	CcSEcCtD
Carfilzomib—ABCB1—pituitary gland—obesity	0.000676	0.00299	CbGeAlD
Carfilzomib—Chills—Topiramate—obesity	0.000676	0.00209	CcSEcCtD
Carfilzomib—ABCB1—adipose tissue—obesity	0.000673	0.00297	CbGeAlD
Carfilzomib—Body temperature increased—Bupropion—obesity	0.000664	0.00205	CcSEcCtD
Carfilzomib—Diarrhoea—Sibutramine—obesity	0.000659	0.00203	CcSEcCtD
Carfilzomib—Dizziness—Orlistat—obesity	0.000658	0.00203	CcSEcCtD
Carfilzomib—Dizziness—Sibutramine—obesity	0.000637	0.00197	CcSEcCtD
Carfilzomib—Back pain—Topiramate—obesity	0.000634	0.00196	CcSEcCtD
Carfilzomib—ABCB1—digestive system—obesity	0.000634	0.0028	CbGeAlD
Carfilzomib—Vomiting—Orlistat—obesity	0.000633	0.00195	CcSEcCtD
Carfilzomib—Muscle spasms—Topiramate—obesity	0.00063	0.00195	CcSEcCtD
Carfilzomib—Headache—Orlistat—obesity	0.000623	0.00192	CcSEcCtD
Carfilzomib—Vomiting—Sibutramine—obesity	0.000612	0.00189	CcSEcCtD
Carfilzomib—Anaemia—Topiramate—obesity	0.000606	0.00187	CcSEcCtD
Carfilzomib—ABCB1—adrenal gland—obesity	0.000604	0.00267	CbGeAlD
Carfilzomib—Headache—Sibutramine—obesity	0.000603	0.00186	CcSEcCtD
Carfilzomib—Asthenia—Bupropion—obesity	0.000602	0.00186	CcSEcCtD
Carfilzomib—Nausea—Orlistat—obesity	0.000591	0.00182	CcSEcCtD
Carfilzomib—Leukopenia—Topiramate—obesity	0.000587	0.00181	CcSEcCtD
Carfilzomib—Diarrhoea—Bupropion—obesity	0.000574	0.00177	CcSEcCtD
Carfilzomib—Nausea—Sibutramine—obesity	0.000572	0.00177	CcSEcCtD
Carfilzomib—Cough—Topiramate—obesity	0.000572	0.00177	CcSEcCtD
Carfilzomib—Hypertension—Topiramate—obesity	0.000566	0.00175	CcSEcCtD
Carfilzomib—Arthralgia—Topiramate—obesity	0.000558	0.00172	CcSEcCtD
Carfilzomib—Dizziness—Bupropion—obesity	0.000555	0.00171	CcSEcCtD
Carfilzomib—Vomiting—Bupropion—obesity	0.000534	0.00165	CcSEcCtD
Carfilzomib—Infection—Topiramate—obesity	0.000531	0.00164	CcSEcCtD
Carfilzomib—Headache—Bupropion—obesity	0.000526	0.00162	CcSEcCtD
Carfilzomib—ABCB1—endocrine gland—obesity	0.000524	0.00231	CbGeAlD
Carfilzomib—Thrombocytopenia—Topiramate—obesity	0.000524	0.00162	CcSEcCtD
Carfilzomib—Anorexia—Topiramate—obesity	0.00051	0.00157	CcSEcCtD
Carfilzomib—Nausea—Bupropion—obesity	0.000499	0.00154	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Topiramate—obesity	0.000487	0.0015	CcSEcCtD
Carfilzomib—Insomnia—Topiramate—obesity	0.000484	0.00149	CcSEcCtD
Carfilzomib—Dyspnoea—Topiramate—obesity	0.000477	0.00147	CcSEcCtD
Carfilzomib—ABCB1—liver—obesity	0.000472	0.00209	CbGeAlD
Carfilzomib—Decreased appetite—Topiramate—obesity	0.000465	0.00144	CcSEcCtD
Carfilzomib—Fatigue—Topiramate—obesity	0.000461	0.00142	CcSEcCtD
Carfilzomib—Pain—Topiramate—obesity	0.000457	0.00141	CcSEcCtD
Carfilzomib—Constipation—Topiramate—obesity	0.000457	0.00141	CcSEcCtD
Carfilzomib—Body temperature increased—Topiramate—obesity	0.000423	0.00131	CcSEcCtD
Carfilzomib—Asthenia—Topiramate—obesity	0.000384	0.00118	CcSEcCtD
Carfilzomib—Diarrhoea—Topiramate—obesity	0.000366	0.00113	CcSEcCtD
Carfilzomib—Dizziness—Topiramate—obesity	0.000354	0.00109	CcSEcCtD
Carfilzomib—Vomiting—Topiramate—obesity	0.00034	0.00105	CcSEcCtD
Carfilzomib—Headache—Topiramate—obesity	0.000335	0.00103	CcSEcCtD
Carfilzomib—Nausea—Topiramate—obesity	0.000318	0.000981	CcSEcCtD
Carfilzomib—PSMB2—Adaptive Immune System—AKT1—obesity	2e-05	4.58e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—obesity	1.99e-05	4.57e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LPA—obesity	1.97e-05	4.52e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—AKT1—obesity	1.97e-05	4.52e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—PIK3CA—obesity	1.96e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—POMC—obesity	1.96e-05	4.48e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—POMC—obesity	1.96e-05	4.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—POMC—obesity	1.96e-05	4.48e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—PIK3CA—obesity	1.95e-05	4.47e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—INS—obesity	1.95e-05	4.46e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—INS—obesity	1.95e-05	4.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—INS—obesity	1.95e-05	4.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LPIN1—obesity	1.93e-05	4.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—POMC—obesity	1.93e-05	4.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—INS—obesity	1.92e-05	4.4e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL2—obesity	1.91e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL2—obesity	1.91e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL2—obesity	1.91e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOA5—obesity	1.89e-05	4.33e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL2—obesity	1.89e-05	4.32e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CB—obesity	1.88e-05	4.32e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CB—obesity	1.88e-05	4.32e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CB—obesity	1.88e-05	4.32e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—STAT3—obesity	1.88e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—STAT3—obesity	1.88e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—STAT3—obesity	1.88e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IGF1—obesity	1.88e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IGF1—obesity	1.88e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IGF1—obesity	1.88e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT2—obesity	1.88e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT2—obesity	1.88e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT2—obesity	1.88e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—obesity	1.87e-05	4.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—obesity	1.87e-05	4.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—obesity	1.87e-05	4.28e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CB—obesity	1.86e-05	4.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—STAT3—obesity	1.86e-05	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IGF1—obesity	1.86e-05	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT2—obesity	1.85e-05	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—obesity	1.84e-05	4.22e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—obesity	1.82e-05	4.16e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PIK3CA—obesity	1.81e-05	4.15e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CD—obesity	1.81e-05	4.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CD—obesity	1.81e-05	4.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CD—obesity	1.81e-05	4.14e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—obesity	1.81e-05	4.14e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CLOCK—obesity	1.8e-05	4.13e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC22A1—obesity	1.8e-05	4.13e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—PPARA—obesity	1.8e-05	4.13e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PIK3CA—obesity	1.8e-05	4.13e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—obesity	1.8e-05	4.12e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SERPINE1—obesity	1.79e-05	4.1e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SERPINE1—obesity	1.79e-05	4.1e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SERPINE1—obesity	1.79e-05	4.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CD—obesity	1.78e-05	4.08e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SERPINE1—obesity	1.76e-05	4.04e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SULT2A1—obesity	1.76e-05	4.03e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GLP1R—obesity	1.76e-05	4.03e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK8—obesity	1.76e-05	4.03e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK8—obesity	1.75e-05	4.01e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—obesity	1.74e-05	3.99e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—obesity	1.74e-05	3.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—obesity	1.74e-05	3.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TYK2—obesity	1.74e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TYK2—obesity	1.74e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TYK2—obesity	1.74e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—obesity	1.74e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—obesity	1.74e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—obesity	1.74e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—obesity	1.74e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—DPYD—obesity	1.73e-05	3.96e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—obesity	1.73e-05	3.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—RHOA—obesity	1.72e-05	3.95e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—RHOA—obesity	1.72e-05	3.95e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—RHOA—obesity	1.72e-05	3.95e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—obesity	1.72e-05	3.93e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TYK2—obesity	1.71e-05	3.93e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—obesity	1.71e-05	3.93e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NOS3—obesity	1.71e-05	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NOS3—obesity	1.71e-05	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3R1—obesity	1.71e-05	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3R1—obesity	1.71e-05	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3R1—obesity	1.71e-05	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NOS3—obesity	1.71e-05	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RHOA—obesity	1.7e-05	3.89e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—APOA1—obesity	1.69e-05	3.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NOS3—obesity	1.68e-05	3.85e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3R1—obesity	1.68e-05	3.85e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PRKAR2B—obesity	1.66e-05	3.81e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—DCN—obesity	1.65e-05	3.79e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—obesity	1.62e-05	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—obesity	1.62e-05	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—obesity	1.62e-05	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—obesity	1.61e-05	3.69e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—obesity	1.61e-05	3.69e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—obesity	1.61e-05	3.69e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CPT1A—obesity	1.61e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—obesity	1.61e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—obesity	1.6e-05	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—obesity	1.6e-05	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—obesity	1.6e-05	3.66e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—obesity	1.59e-05	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—obesity	1.59e-05	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—obesity	1.59e-05	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—obesity	1.59e-05	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—obesity	1.59e-05	3.64e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—obesity	1.58e-05	3.63e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NAMPT—obesity	1.58e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MTOR—obesity	1.58e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MTOR—obesity	1.58e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CB—obesity	1.58e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CB—obesity	1.58e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MTOR—obesity	1.58e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CB—obesity	1.58e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GCK—obesity	1.57e-05	3.59e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LIPC—obesity	1.57e-05	3.59e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOC3—obesity	1.56e-05	3.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MTOR—obesity	1.55e-05	3.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CB—obesity	1.55e-05	3.56e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—obesity	1.52e-05	3.47e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CETP—obesity	1.51e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—obesity	1.51e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SDC1—obesity	1.49e-05	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—obesity	1.49e-05	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—obesity	1.49e-05	3.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—obesity	1.49e-05	3.4e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—obesity	1.49e-05	3.4e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—obesity	1.49e-05	3.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—obesity	1.49e-05	3.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—obesity	1.48e-05	3.4e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—obesity	1.48e-05	3.4e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—obesity	1.48e-05	3.39e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—obesity	1.47e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKR1C3—obesity	1.47e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—obesity	1.46e-05	3.35e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SCARB1—obesity	1.45e-05	3.32e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SREBF1—obesity	1.41e-05	3.22e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—obesity	1.37e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—obesity	1.37e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—obesity	1.37e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—obesity	1.37e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—obesity	1.37e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—obesity	1.37e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GOT2—obesity	1.37e-05	3.13e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—obesity	1.35e-05	3.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—obesity	1.35e-05	3.09e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—obesity	1.34e-05	3.07e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—FASN—obesity	1.34e-05	3.07e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—BCHE—obesity	1.33e-05	3.05e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK8—obesity	1.33e-05	3.05e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK8—obesity	1.33e-05	3.05e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK8—obesity	1.33e-05	3.05e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—obesity	1.32e-05	3.01e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—obesity	1.32e-05	3.01e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—obesity	1.32e-05	3.01e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK8—obesity	1.31e-05	3.01e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—obesity	1.3e-05	2.97e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2E1—obesity	1.29e-05	2.94e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NQO1—obesity	1.27e-05	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—obesity	1.27e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—obesity	1.26e-05	2.89e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—obesity	1.24e-05	2.84e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—obesity	1.23e-05	2.82e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC2A4—obesity	1.22e-05	2.79e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GCG—obesity	1.22e-05	2.79e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—obesity	1.22e-05	2.79e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—obesity	1.22e-05	2.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—obesity	1.22e-05	2.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—obesity	1.21e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—obesity	1.21e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—obesity	1.21e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—obesity	1.21e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—obesity	1.21e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—obesity	1.21e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—obesity	1.21e-05	2.76e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—obesity	1.21e-05	2.76e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—obesity	1.21e-05	2.76e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYCS—obesity	1.2e-05	2.76e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—obesity	1.2e-05	2.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—obesity	1.2e-05	2.74e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—obesity	1.2e-05	2.74e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—obesity	1.19e-05	2.73e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GGT1—obesity	1.18e-05	2.7e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GOT1—obesity	1.18e-05	2.7e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOA1—obesity	1.16e-05	2.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—obesity	1.15e-05	2.63e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—obesity	1.15e-05	2.63e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—obesity	1.15e-05	2.63e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—STK11—obesity	1.15e-05	2.62e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP19A1—obesity	1.15e-05	2.62e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—obesity	1.13e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—obesity	1.13e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—obesity	1.13e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—obesity	1.13e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—obesity	1.13e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—obesity	1.13e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—obesity	1.13e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—obesity	1.12e-05	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—obesity	1.12e-05	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—obesity	1.12e-05	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—obesity	1.12e-05	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—obesity	1.12e-05	2.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—obesity	1.12e-05	2.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—obesity	1.11e-05	2.55e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—obesity	1.1e-05	2.53e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—COMT—obesity	1.07e-05	2.44e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARGC1A—obesity	1.05e-05	2.41e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNB3—obesity	1.05e-05	2.41e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HMOX1—obesity	1.05e-05	2.4e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—obesity	1.04e-05	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—obesity	1.03e-05	2.36e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNAS—obesity	1.02e-05	2.34e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOB—obesity	1e-05	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—obesity	9.6e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—obesity	9.6e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—obesity	9.6e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LPL—obesity	9.56e-06	2.19e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—obesity	9.47e-06	2.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—obesity	9.38e-06	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—obesity	9.38e-06	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—obesity	9.38e-06	2.15e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GPX1—obesity	9.33e-06	2.14e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—obesity	9.25e-06	2.12e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CD36—obesity	9.08e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—obesity	8.61e-06	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—obesity	8.5e-06	1.95e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—obesity	8.5e-06	1.95e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—obesity	8.5e-06	1.95e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARA—obesity	8.45e-06	1.94e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—obesity	8.38e-06	1.92e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AGT—obesity	8.18e-06	1.87e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOE—obesity	8.01e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CAV1—obesity	7.94e-06	1.82e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOA1—obesity	7.92e-06	1.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—obesity	7.84e-06	1.8e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—obesity	7.84e-06	1.8e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—obesity	7.84e-06	1.8e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—obesity	7.73e-06	1.77e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—obesity	7.23e-06	1.66e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—obesity	6.98e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—POMC—obesity	6.88e-06	1.58e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—INS—obesity	6.85e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CD—obesity	6.36e-06	1.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—obesity	6.28e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NOS3—obesity	6e-06	1.38e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3R1—obesity	6e-06	1.38e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CB—obesity	5.54e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—obesity	5.49e-06	1.26e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—obesity	3.38e-06	7.74e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—obesity	2.76e-06	6.32e-06	CbGpPWpGaD
